Abstract:BackgroundDuchenne Muscular Dystrophy (DMD) is the most common muscle disease in children, and there are no effective therapies for DMD or Becker Muscular Dystrophy (BMD). Currently, targeted gene therapy treatments have emerged. As a result, genetic diagnosis is the basis of treatment. In addition, genetic and prenatal diagnosis significantly reduces their incidence rates. This study combines the application of multiplex ligation-dependent probe amplification technology (MLPA) and "next-generation" sequencing technology (NGS) as the most economical and efficient method of diagnosis. Therefore, in the diagnosis of DMD/BMD, patients' MLPA data are first used to detect DMD gene deletions or duplications, and NGS and Sanger sequencing are then applied to exclude MLPA-negative samples. Meanwhile, polymerase chain reaction (PCR) is used to detect single exon deletions to exclude false-positives in MLPA caused by point mutations.MethodsIn this study, we recruited 1051 proband families of DMD from 2016 to 2018 and had access to information that could identify individual participants during or after data collection. Patients who were diagnosed with DMD were first tested by MLPA. MLPA results with single exon deletions were validated with PCR amplification and Sanger sequencing. The negative results of MLPA were further analysed with NGS and validated by Sanger sequencing. For novel missense mutations, phenotype-genotype correlations were analysed using PolyPhen2 and mutation taster. All methods were performed in accordance with the relevant guidelines and regulations.ResultsDMD mutations were identified in 1029 families (97.91%, 1029/1051). Large deletions, duplications, and small mutations accounted for 70.41% (740/1051), 8.28% (87/1051), and 19.12% (201/1051) of all cases, respectively. There were 205 small mutation types, 53 of which were novel. The rate of de novo mutations was 39.45% (187/474) and was higher in large duplications (49.53%, 157/317). Among 68 asymptomatic patients (< 3 years old) with unexplained persistent hyperCKaemia upon conventional physical examination, 63 were diagnosed as DMD/BMD according to genetic diagnosis.ConclusionOur results expand the spectrum of DMD mutations, which could contribute to the treatment of DMD/BMD and provide an effective diagnosis method. Thus, the combination of MLPA, NGS and Sanger sequencing is of great significance for family analysis, gene diagnosis and gene therapy.

Combined screening of multiplex polymerase chain reaction and denaturing high-performance liquid chromatography in Duchenne muscular dystrophy with mutation deletion

Detection of duplication mutation and carriers of Duchenne/Becker muscular dystrophy by multiplex ligation-dependent probe amplification quantitative

Screening of Duchenne Muscular Dystrophy (DMD) Mutations and Investigating Its Mutational Mechanism in Chinese Patients.

Genetic Identification of Pathogenic Variations of the DMD Gene: a Retrospective Study from 10,481 Neonatal Patients Based on Next-Generation Sequencing Data

Primary Study on Prenatal Diagnosis of Duchenne Muscular Dystrophy

Targeted Next-Generation Sequencing As a Comprehensive Test for Patients with and Female Carriers of DMD/BMD: a Multi-Population Diagnostic Study

Development of a Comprehensive Real-Time PCR Assay for Dystrophin Gene Analysis and Prenatal Diagnosis of Chinese Families.

Comprehensive Genetic Diagnosis of Patients with Duchenne/Becker Muscular Dystrophy (DMD/BMD) and Pathogenicity Analysis of Splice Site Variants in the DMD Gene

[Evaluation of Detection and Analysis of Chromosome 22q11.2 Microdeletion by Multiple Ligation-Dependent Probe Amplification Assay].

Evaluation of detection and analysis of chromosome 22ql 1.2 microdeletion by multiple ligation-dependent probe amplification assay

A Resolved Discrepancy Between Multiplex PCR and Multiplex Ligation‐dependent Probe Amplification by Targeted Next‐generation Sequencing Discloses a Novel Partial Exonic Deletion in the Duchenne Muscular Dystrophy Gene

Detection of duplications or deletions of the PMP22 gene using real-time quantitative PCR]

Study on Duchenne muscular dystrophy gene mutation and prenatal diagnosis]

Population-Wide Duchenne Muscular Dystrophy Carrier Detection by CK and Molecular Testing

Characteristics of Dystrophin Gene Mutations among Chinese Patients As Revealed by Multiplex Ligation–Dependent Probe Amplification

Genetic analysis of 1051 Chinese families with Duchenne/Becker Muscular Dystrophy

[Genotype, Phenotype Analysis and Follow-Up Study on Patients with Duchenne/Becker Muscular Dystrophy].

Rapid Diagnosis of Spinal Muscular Atrophy Using Denaturing High-Performance Liquid Chromatography

Single Cell Analysis of DMD Gene and SRY Gene Using Whole Genome Amplification

[Mutation analysis and prenatal diagnosis of sporadic DMD/BMD families].

[Carrier screening model for Duchenne muscular dystrophy for women of reproductive age based on a pre-pregnancy birth defect control platform].